| Biomarker ID | 98 |
| PMID | 15666387 |
| Year | 2005 |
| Biomarker | Thymosin b15 (Tb15) |
| Biomarker Basis | Concentration Based (ng/dl)/(μg/mg) |
| Biomolecule | Protein |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 12.0 (95% CI: 2.8-51.8) |
| Effect on Pathways | Pathways Include:-PAK5 human kinase ARCHS4 coexpression, EPHA4 human kinase ARCHS4 coexpression,ACVR2B human kinase ARCHS4 coexpression,MAP3K13 human kinase ARCHS4 coexpression,EPHA7 human kinase ARCHS4 coexpression |
| Experiment | ADT treated Prostate Cancer Vs Controls |
| Type of Biomarker | Diagnostic |
| Cohort | Patients with Prostate Cancer, including 61 patients prior to therapy (PCa untreated), 46 patients who received a Radical Prostatectomy and no PSA faliure for 2 years, and 14 patients receiving androgen deprivation therapy (ADT) for metastatic disease. Control Group consisted of 52 healthy subjects out of which 15 had history of nephrolithiasis but no active disease. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.001 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TMSB15A |